Пожалуйста, используйте этот идентификатор, чтобы цитировать или ссылаться на этот ресурс: http://elar.urfu.ru/handle/10995/111712
Полная запись метаданных
Поле DCЗначениеЯзык
dc.contributor.authorZerkalenkova, E.en
dc.contributor.authorLebedeva, S.en
dc.contributor.authorBorkovskaia, A.en
dc.contributor.authorSoldatkina, O.en
dc.contributor.authorPlekhanova, O.en
dc.contributor.authorTsaur, G.en
dc.contributor.authorMaschan, M.en
dc.contributor.authorMaschan, A.en
dc.contributor.authorNovichkova, G.en
dc.contributor.authorOlshanskaya, Y.en
dc.date.accessioned2022-05-12T08:21:08Z-
dc.date.available2022-05-12T08:21:08Z-
dc.date.issued2021-
dc.identifier.citationBTK, NuTM2A, and PRPF19 are Novel KMT2A Partner Genes in Childhood Acute Leukemia / E. Zerkalenkova, S. Lebedeva, A. Borkovskaia et al. // Biomedicines. — 2021. — Vol. 9. — Iss. 8. — 924.en
dc.identifier.issn2227-9059-
dc.identifier.otherAll Open Access, Gold, Green3
dc.identifier.urihttp://elar.urfu.ru/handle/10995/111712-
dc.description.abstractChromosomal rearrangements of the human KMT2A/MLL gene are associated with acute leukemias, especially in infants. KMT2A is rearranged with a big variety of partner genes and in multiple breakpoint locations. Detection of all types of KMT2A rearrangements is an essential part of acute leukemia initial diagnostics and follow-up, as it has a strong impact on the patients’ outcome. Due to their high heterogeneity, KMT2A rearrangements are most effectively uncovered by next-generation sequencing (NGS), which, however, requires a thorough prescreening by cytogenetics. Here, we aimed to characterize uncommon KMT2A rearrangements in childhood acute leukemia by conventional karyotyping, FISH, and targeted NGS on both DNA and RNA level with subse-quent validation. As a result of this comprehensive approach, three novel KMT2A rearrangements were discovered: ins(X;11)(q26;q13q25)/KMT2A-BTK, t(10;11)(q22;q23.3)/KMT2A-NUTM2A, and inv(11)(q12.2q23.3)/KMT2A-PRPF19. These novel KMT2A-chimeric genes expand our knowledge of the mechanisms of KMT2A-associated leukemogenesis and allow tracing the dynamics of minimal residual disease in the given patients. © 2021 by the authors. Licensee MDPI, Basel, Switzerland.en
dc.description.sponsorshipFunding: KMT2A rearrangement assessment was supported by the Russian Science Foundation (grant no. 19-75-10056). Quantitative RT-PCR for MRD monitoring was supported by Russian Presidential (grant no. MK-1645.2020.7).en
dc.format.mimetypeapplication/pdfen
dc.language.isoenen
dc.publisherMDPI AGen1
dc.publisherMDPI AGen
dc.relationinfo:eu-repo/grantAgreement/RSF//19-75-10056en
dc.rightsinfo:eu-repo/semantics/openAccessen
dc.sourceBiomedicines2
dc.sourceBiomedicinesen
dc.subjectCYTOGENETICSen
dc.subjectFUSION GENESen
dc.subjectKMT2Aen
dc.subjectNGSen
dc.subjectPEDIATRIC ACUTE LEUKEMIAen
dc.titleBTK, NuTM2A, and PRPF19 are Novel KMT2A Partner Genes in Childhood Acute Leukemiaen
dc.typeArticleen
dc.typeinfo:eu-repo/semantics/articleen
dc.typeinfo:eu-repo/semantics/publishedVersionen
dc.identifier.doi10.3390/biomedicines9080924-
dc.identifier.scopus85112617674-
local.contributor.employeeZerkalenkova, E., Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, 117997, Russian Federation; Lebedeva, S., Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, 117997, Russian Federation; Borkovskaia, A., Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, 117997, Russian Federation; Soldatkina, O., Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, 117997, Russian Federation; Plekhanova, O., Regional Children Hospital 1, Pediatric Oncology and Hematology Center, Research Institute of Medical Cell Technologies, Ural Federal University Named after the First President of Russia BN Yeltsin, Ekaterinburg, 620149, Russian Federation; Tsaur, G., Regional Children Hospital 1, Pediatric Oncology and Hematology Center, Research Institute of Medical Cell Technologies, Ural Federal University Named after the First President of Russia BN Yeltsin, Ekaterinburg, 620149, Russian Federation; Maschan, M., Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, 117997, Russian Federation; Maschan, A., Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, 117997, Russian Federation; Novichkova, G., Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, 117997, Russian Federation; Olshanskaya, Y., Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, 117997, Russian Federationen
local.issue8-
local.volume9-
dc.identifier.wos000688995200001-
local.contributor.departmentDmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, 117997, Russian Federation; Regional Children Hospital 1, Pediatric Oncology and Hematology Center, Research Institute of Medical Cell Technologies, Ural Federal University Named after the First President of Russia BN Yeltsin, Ekaterinburg, 620149, Russian Federationen
local.identifier.pure22981580-
local.description.order924-
local.identifier.eid2-s2.0-85112617674-
local.fund.rsf19-75-10056-
local.identifier.wosWOS:000688995200001-
Располагается в коллекциях:Научные публикации ученых УрФУ, проиндексированные в SCOPUS и WoS CC

Файлы этого ресурса:
Файл Описание РазмерФормат 
2-s2.0-85112617674.pdf1,37 MBAdobe PDFПросмотреть/Открыть


Все ресурсы в архиве электронных ресурсов защищены авторским правом, все права сохранены.